AI Article Synopsis

  • - The study aimed to evaluate how effective and safe a combination of Loratadine and Glucocorticoid nasal spray is for treating kids with bronchial asthma and seasonal allergies.
  • - 100 pediatric patients were divided into two groups—one received only the nasal spray (control), while the other got both the nasal spray and Loratadine (observation)—and their outcomes were monitored over 90 days.
  • - The results showed that the combination treatment significantly improved asthma and rhinitis symptoms without increasing side effects, suggesting it's a promising approach for clinical use.

Article Abstract

Objective: To investigate the clinical efficacy and safety of Loratadine combined with Glucocorticoid nasal spray in the treatment of pediatric bronchial asthma with seasonal allergic rhinitis.

Methods: A total of 100 pediatric patients with moderate to severe bronchial asthma and seasonal allergic rhinitis admitted to our hospital between January 2020 and January 2023 were included in this study. All patients met the complete inclusion and exclusion criteria. Based on different treatment interventions, they were divided into the control group ( = 50) and the observation group ( = 50). Patients in the control group received treatment with glucocorticoid nasal spray, while patients in the observation group received combined intervention with Loratadine in addition to the treatment received by the control group. The clinical treatment outcomes, incidence of adverse reactions, as well as the scores of nasal symptoms, asthma control, and peak expiratory flow rates at different treatment time points (baseline, T1: 30 days after treatment, T2: 60 days after treatment, T3: 90 days after treatment) were compared between the two groups. The combined treatment of Loratadine with Glucocorticoid nasal spray demonstrates significant clinical efficacy in the treatment of pediatric bronchial asthma with seasonal allergic rhinitis. It further promotes the recovery of peak expiratory flow rates, improves symptoms of rhinitis and asthma in pediatric patients. Importantly, the application of this combined treatment does not increase the risk of adverse reactions in pediatric patients, indicating its high safety profile. This treatment approach is worthy of clinical application and further promotion.

Download full-text PDF

Source
http://dx.doi.org/10.1080/02770903.2024.2379410DOI Listing

Publication Analysis

Top Keywords

glucocorticoid nasal
16
nasal spray
16
bronchial asthma
16
asthma seasonal
16
seasonal allergic
16
treatment
14
clinical efficacy
12
treatment pediatric
12
pediatric bronchial
12
allergic rhinitis
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!